PFIZER INC (PFE)

US7170811035 - Common Stock

29.6  -0.37 (-1.23%)

After market: 29.66 +0.06 (+0.2%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PFIZER INC

NYSE:PFE (7/22/2024, 7:04:00 PM)

After market: 29.66 +0.06 (+0.2%)

29.6

-0.37 (-1.23%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month7.75%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap167.73B
Shares
PE20.85
Fwd PE10.74
Dividend Yield5.65%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PFE Daily chart

Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 88,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Company Info

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK 10017

P: 12127332323

CEO: Albert Bourla

Employees: 88000

Website: https://www.pfizer.com/

PFE News

ChartMill News Image12 hours ago - ChartmillWhich S&P500 stocks are the most active on Monday?

Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.

News Image20 hours ago - The Motley FoolBetter Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche

Neither is a leader right now, but one of them might be on track to change that.

News Image2 days ago - The Motley FoolBillionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

News Image3 days ago - The Motley FoolCould Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.

The pharma's latest push to develop a weight loss pill isn't going well.

News Image4 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Pfizer
News Image4 days ago - ForbesWeight Loss Pills Intensify Obesity Drug Race—But Here’s Why Experts Say Injections Aren’t Going Anywhere

Competition is mounting in the weight loss sector as giants like Eli Lilly, Roche, Novo Nordisk and Pfizer explore oral weight loss drugs that could be a boon to people wanting a needle-free weight loss option.

PFE Twits

Here you can normally see the latest stock twits on PFE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example